Volume 133, Issue 18



May 2, 2019 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: Dominant activating RAC2 mutation causes both neutrophil and lymphocyte defects. See the article by Hsu et al.

The global clonal complexity of the murine blood system declines throughout life and after serial transplantation
In a Plenary Paper, Ganuza et al examine whether steady-state hematopoiesis in the aging mouse displays a decline in clonal complexity reflecting human clonal hematopoiesis of indeterminate potential (CHIP). As with human hematopoietic stem cells, they demonstrate loss of heterogeneity and myeloid skewing, but studies implicate different gene mutations from those in humans.

Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial
Zelenetz and colleagues report on phase 1b results of a trial combining venetoclax with R-CHOP or G-CHOP for the treatment of non-Hodgkin lymphoma, demonstrating very high response rates and manageable toxicity.

Sensitization of nociceptors by prostaglandin E2–glycerol contributes to hyperalgesia in mice with sickle cell disease
Khasabova et al examine the role of prostaglandin E2–glycerol (PGE2-G) in sickle cell chronic pain. In a mouse model of sickle cell disease (SCD), they demonstrate that PGE2-G production is increased in SCD mice and that inhibiting PGE2-G production or its receptor decreases pain, offering a potential nonopioid target for control of chronic pain in SCD.

Mitochondria in the maintenance of hematopoietic stem cells: new perspectives and opportunities
Filippi and Ghaffari review the critical role of mitochondria in hematopoietic stem cell (HSC) maintenance, as well as in HSC commitment and differentiation.

Dominant activating RAC2 mutation with lymphopenia, immunodeficiency, and cytoskeletal defects
Hsu et al describe a new immunodeficiency syndrome caused by a dominant activating mutation in RAC2 that is associated with defects in both neutrophil and lymphocyte function.

Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma
Facon and colleagues present results of a phase 3 trial comparing carfilzomib to bortezomib in combination with melphalan-prednisone for newly diagnosed myeloma in transplant-ineligible patients.

View this week's complete table of contents

Why Submit to Blood?


Blood (, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.